Haisco Unit and Eli Lilly Enter Collaboration and Licensing Deals

• Haisco's unit is eligible for up to $87 million in upfront and near-term payments
• Additional milestone-based payments could reach about $3 billion tied to clinical, regulatory, and commercialization achievements
• The agreement continues a trend of foreign drugmakers investing in Chinese biotech development pipelines, with Lilly having similar partnerships with other Chinese drugmakers

Summary: Haisco Unit and Eli Lilly Enter Collaboration and Licensing Deals

Key Deal Terms:

U.S. pharmaceutical giant Eli Lilly has signed a collaboration and licensing agreement with a unit of China's Haisco Pharmaceutical Group for experimental medicines. The deal includes potential milestone payments totaling approximately $3 billion, with $87 million in upfront and near-term payments.

Geographic Rights:

Under the agreement, Eli Lilly will obtain worldwide rights to selected Haisco unit assets, excluding mainland China, Hong Kong, Macau, and Taiwan. The deal focuses on innovative drug projects currently in development.

Payment Structure:

The $3 billion in potential payments are tied to achieving clinical, regulatory, and commercialization-related milestones, representing a significant incentive structure for successful drug development.

Market Context:

This deal represents the latest example of growing interest from foreign pharmaceutical companies in China's biotech sector and development pipelines. Eli Lilly has been actively expanding its partnerships in China, having previously entered collaborations with other Chinese drugmakers including Hutchmed.

Industry Implications:

The agreement highlights the increasing value of Chinese biotech innovation to global pharmaceutical companies and suggests continued cross-border collaboration in drug development. For Eli Lilly, this expands its pipeline access and geographic diversification strategy, while Haisco gains significant potential revenue and validation for its research programs.

The announcement was made through a filing to the Shenzhen stock exchange on June 1.